Efficacy and safety of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor harboring secondary mutation with exon 17: Interim report of a phase II trial.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e22511-e22511 ◽  
Author(s):  
Chun-Nan Yeh
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Stromal Tumor ◽  
Secondary Mutation ◽  
Efficacy And Safety ◽  
Interim Report

Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 10015-10015 ◽  
Author(s):  
T. Nishida ◽  
A. Sawaki ◽  
T. Doi ◽  
Y. Yamada ◽  
Y. Komatsu ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Stromal Tumor ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

Oncotarget ◽  
2017 ◽  
Vol 8 (27) ◽  
pp. 44121-44130 ◽  
Author(s):  
Chun-Nan Yeh ◽  
Ming-Huang Chen ◽  
Yen-Yang Chen ◽  
Ching-Yao Yang ◽  
Chueh-Chuan Yen ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Stromal Tumor

scholarly journals A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor

2019 ◽  
Vol 25 (21) ◽  
pp. 6302-6308 ◽  
Author(s):  
John Glod ◽  
Fernanda I. Arnaldez ◽  
Lori Wiener ◽  
Melissa Spencer ◽  
J. Keith Killian ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Succinate Dehydrogenase ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Stromal Tumor
Sign in / Sign up

Export Citation Format

Share Document